Mannitol B. Braun

Mannitol, the active ingredient in Mannitol B. Braun, is an osmotic diuretic presented as an intravenous solution for intravenous use. It is employed to lower elevated intracranial pressure, manage cerebral edema, promote diuresis in acute renal failure, and reduce intraocular pressure in patients requiring rapid fluid shifts.

GNH USA supplies Mannitol B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mannitol is used in clinical situations that require rapid osmotic fluid removal or pressure reduction.

- Elevated intracranial pressure: rapidly lowers intracranial pressure to protect brain tissue. - Cerebral edema: draws fluid out of swollen brain tissue to improve neurological function. - Acute renal failure: enhances renal excretion of water and electrolytes to support diuresis. - Intraocular pressure: reduces pressure in the eye during acute glaucoma attacks. - Toxin elimination: facilitates renal clearance of certain nephrotoxic substances.

Mannitol may cause a range of adverse reactions, from mild to severe, depending on patient factors and dosing.

Common Side Effects: - Headache: mild to moderate discomfort. - Nausea or vomiting: gastrointestinal upset. - Electrolyte imbalance: changes in sodium or potassium levels. - Transient hypotension: brief drop in blood pressure. - Fluid overload: signs of pulmonary edema in susceptible patients.

Serious or Rare Side Effects: - Acute renal failure: worsening kidney function. - Severe electrolyte disturbances: hypernatremia or hyponatremia. - Anaphylactic reaction: rare hypersensitivity. - Hemolysis: especially in patients with G6PD deficiency. - Pulmonary edema: rapid fluid shifts leading to respiratory compromise.

Mannitol requires careful monitoring and specific patient considerations before and during therapy.

- Renal function: assess baseline kidney function and monitor creatinine. - Electrolytes: check serum sodium, potassium, and osmolality regularly. - Cardiovascular status: avoid rapid infusion in patients with heart failure. - Pregnancy: use only if benefits outweigh risks (Category C). - Pediatric use: dose adjustments needed; monitor growth parameters. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can alter the pharmacokinetics of several co‑administered agents, requiring vigilance.

Major Interactions (Avoid): - Loop diuretics: may exacerbate electrolyte loss and volume depletion. - Lithium: increased risk of lithium toxicity due to altered renal clearance. - Aminoglycosides: heightened nephrotoxicity risk.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive hypotensive effect. - Insulin or oral hypoglycemics: monitor blood glucose as osmotic shifts may affect levels. - Contrast media: increased risk of renal impairment when combined.